Introduction {#S0001}
============

Melasma is a general disorder of hyperpigmentation and usually involves the face and neck. Hyperpigmentation is particularly common in darker complected patients and is often hard to treat \[[@CIT0001]\]. Skin-lightening agents are used to treat hyperpigmentation. Researchers have discovered and conducted various *in vivo* and *in vitro* studies on skin-lightening agents. Arbutin, hydroquinone and several plant extracts are tried to achieve the skin-lightening effect and are being used in cosmetics. Skin-lightening agents inhibit the conversion of tyrosine to melanin by the enzyme tyrosinase, thus tyrosinase is the rate-limiting enzyme in melanin synthesis. Tyrosinase is a copper-containing enzyme that catalyzes melanin biosynthesis in three steps: the hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA), oxidation of DOPA to DOPA quinone and oxidation of 5,6-dihydroxyindole to indolequinone. Tyrosinase inhibitors play a vital role as skin-lightening agents \[[@CIT0002]\].

Many plant extracts have a good inhibitory effect on melanin formation and may be a good choice for cosmetic purposes of whitening facial skin and defense against skin darkening. In addition, they have comparatively less side effects \[[@CIT0003]\]. In cosmetic preparations, many plant extracts such as *Morus alba*, *Acacia bark*, *Glycyrrhiza glabra* and *Green tea* have been used as whitening agents \[[@CIT0004]--[@CIT0007]\].

*Cassia fistula* L, also known as the Golden Shower, is widely used in various countries as an ornamental tree for its beautiful bunches of yellow flowers. Recognized by the British Pharmacopoeia \[[@CIT0008]\], *C. fistula*, a member of the Leguminosae family, is extensively used for its medicinal properties. In the Indian literature, this plant has also been described to be useful in skin diseases \[[@CIT0009], [@CIT0010]\]. *Cassia fistula* is a medicinal plant acknowledged to be rich in phenolics, containing catechin, epicatechin, Kaempferol, ellagic acid (EA) and Rhein \[[@CIT0011]\].

The medicinal value of *Hippophae rhamnoides* was found more than 1000 years ago, but it has been used for making medicines and healthy products by using modern science and technology only for the last 30 years \[[@CIT0012]\]. Various catechin like (+)-gallocatechin and (--)-epigallocatechin have been isolated from *H. rhamnoides* berries \[[@CIT0013]\].

Aim {#S0002}
===

The aim of this study was to investigate the effects of formulations containing phenolic-rich (catechin) extract of *C. fistula* and *H*. *rhamnoides in vitro* and *in vivo*.

Material and methods {#S0003}
====================

Plant materials and preparation of plant extracts {#S20004}
-------------------------------------------------

*Cassia fistula* pods were collected from the Islamia University of Bahawalpur in August. *Hippophae rhamnoides* berries were purchased from Pak Sea Buckthorn International Skardu, Pakistan in May. The identification of the plant materials was performed by a taxonomist, Prof. Dr. Muhammad Arshad at the Cholistan Institute of Desert Studies (CIDS), the Islamia University of Bahawalpur and voucher specimens were preserved (voucher \# OB-LF-4-11-21 and HR-FT-03-11-23) at the herbarium of the Faculty of Pharmacy, Islamia University of Bahawalpur.

Plant materials were air-dried and then powdered. Each powdered plant was extracted with 70% methanol solution, and after filtration, the filtrates were evaporated under vacuum. These extracts were used for further studies of tyrosinase inhibition and emulsion formulations.

Drugs and chemicals {#S20005}
-------------------

Methanol, catechin and gallic acid were obtained from Sigma (St Louis, MO, USA). Paraffin oil, Stearic acid, Tween80, Span20, Bees wax and Cetomacrogol were taken from Merck (Germany).

*In-vitro* tyrosinase inhibitory activity of plant extracts {#S20006}
-----------------------------------------------------------

Tyrosinase inhibitory activity is usually determined using a spectrophotometer. The procedure is briefly described here: a reaction mixture of 100 µl, 40 µl 100 mM phosphate buffer, pH 6.8, 20 µl mushroom tyrosinase enzyme (6 units) and 10 µl 0.5 mM test compound mixed in 96-well plate. The mixture was pre-incubated at 37°C for 5 min. Thirty µl of 10 mM L-dopamine (substrate) was added. Contents were mixed and incubated for 10 min more. Absorbance was taken at λ 490 nm using Synergy HT BioTek 96-well plate reader. The percent enzyme inhibition was calculated as:%Inhibition = 100 -- (Abs of test sample/Abs of control × 100).

We determined the effect of the test compound on tyrosinase inhibition by IC~50~ using EZ-Fit Enzyme Kinetics Software (Perrella Scientific Inc., Amherst, USA).

Preparation of formulations {#S20007}
---------------------------

For investigation of the tyrosinase inhibitory effect of formulations, an oil-in-water (O/W) type emulsion (F1/F2) containing plant extracts and a placebo (F3) without plant extracts were prepared. The composition of the formulations is given in [Table 1](#T0001){ref-type="table"}. The formulations were found stable for pH, centrifugation, electrical conductivity, temperature stability tests at 8 ±0.1°C, 25 ±0.1°C, 40 ±0.1°C and 40 ±0.1°C with 75% relative humidity, physical nature i.e. color, creaming and liquefaction and rheological characteristics.

###### 

Composition of formulations (% w/w)

  Composition       F1/F2   F3
  ----------------- ------- -----
  Liquid paraffin   24      24
  Stearic acid      5       5
  Span 20           2       2
  Bees wax          7       7
  Cetomacrogol      5       5
  Tween 80          6       6
  Plant extract     5       Nil
  Preservative      1       1
  D/W               45      50

*In-vitro* tyrosinase inhibitory activity of formulations {#S20008}
---------------------------------------------------------

Ozer *et al*. method with a slight modification was applied for *in-vitro* tyrosinase inhibitory activity of formulations \[[@CIT0014]\]. Approximately 1.5 gm of F1, F2 and F3 was weighed accurately into a centrifuge tube. Ten ml of methanol (50%) was added and stirred in an ultrasonic bath for 30 min. The suspension was centrifuged at 5000 rpm for 10 min. It was further diluted at a ratio of 1: 10 with 50% methanol and tested by the dopachrome method for determination of tyrosinase inhibitory effect.

Subjects {#S20009}
--------

Two groups of 25 healthy subjects each (aged 21--35) were enrolled in this study after their informed consent was obtained. All volunteers completed the study successfully. None of them had any pathological condition on their cheeks. They were sufficiently informed about the use of products. Moreover, they were told not to use any other skin products, especially whitening agents, throughout the 12-week duration of the study.

*In-vivo* study design {#S20010}
----------------------

A single blinded, placebo-controlled study was conducted to assess the effects of formulations on the improvement of the skin melanin (anti-melasma effects). This study was conducted in October-December and an expert investigator ensured the proper handling of biometrological measurements, allowing for obtaining uniform results. Tests were carried out on both the right and left cheeks of volunteers. Measurements were carried out at baseline and on week 1, 2, 3, 4, 6, 8, 10 and 12.

Approximately 500 mg of formulations were applied to the cheeks twice daily (mornings and evenings) over a period of 12 weeks. Prior to all measurements, volunteers were asked for at least 15 min wait in order to allow for complete skin adjustment to the room temperature.

Ethical considerations {#S20011}
----------------------

The institutional ethics committee of the Faculty of Pharmacy, the Islamia University of Bahawalpur approved the protocol of this study (No. 942/Acad). Before enrollment and inclusion of a volunteer in this study, signed informed consent was obtained from each volunteer.

Instrumental measurements {#S20012}
-------------------------

Biometrologically, a Mexameter^®^ (Courage & Khazaka, Germany) with noninvasive probes was used in this study for assessing the skin melanin. Mexameter^®^ is a narrow-band reflectance spectrophotometer, designed to measure the intensity of skin melanin. It has mainly been used for cosmetic research but recently it has also been used to assess hyperpigmentation of skin (melasma).

Visual survey {#S20013}
-------------

After 12 weeks of treatment, a visual survey was carried out to indicate 3 parameters: change in photograph, change in size and change in pigmentation. Photographs of only those volunteers, who allowed openly for reproduction, were taken.

Mathematical analysis {#S20014}
---------------------

The percentage changes in melanin after every week for each volunteer were calculated by using the following formula:%Change = \[(Tx -- T0)/T0\] × 100, where: T0 -- baseline values, Tx -- value obtained every week.

Statistical analysis {#S20015}
--------------------

The measured values were analyzed using GraphPad Prism version 5 statistical software. A paired sample *t*-test for variation between the active formulation and placebo was performed. Standard Parametric one-way ANOVA with Dunnett Multiple Comparisons Post Test was used to observe the correlation between baseline values and the values at different weeks. Values of *p* of less than 0.005 were considered statistically significant.

Patch Test (Burchard Test) {#S20016}
--------------------------

Prior to sampling, a patch test was performed to find any possible sensitivity of formulations on forearms of each volunteer. A specified area was marked on the forearms. Placebo was applied to the right forearm while the active formulation was applied to the left forearm. The areas were covered with surgical dressing (Patches) saturated with formulations. After 48 h, the patches were removed and the forearms were washed with saline. Scores were noted for the presence of itching/irritation using a 4-point scale ranging from 0 to 3; where 3 stands for severe response, 2 for moderate, 1 for mild and 0 stands for no response. Each volunteer was requested to note the degree of itching/irritation and allocate a score from the same scale.

Results {#S0017}
=======

*In-vitro* tyrosinase inhibitory activity of plant extracts and formulations {#S20018}
----------------------------------------------------------------------------

[Table 2](#T0002){ref-type="table"} summarizes the results of anti-tyrosinase inhibition activity of plant extracts, where inhibition is expressed as IC~50~ values. Results indicate that *H. rhamnoides* had slight poor antityrosinase activity (72% inhibition at 0.05 mg/ml concentration) as compared to *C. fistula* extracts (77% inhibition at 0.05 mg/ml concentration). Evaluation of the formulations on tyrosinase inhibition confirmed that the active formulations (F1 and F2) containing plant extracts at 5% concentration have the inhibitor activity. Placebo without any plant extract was used as a control sample, and no inhibitory effect was observed. Tyrosinase inhibitory effects of formulations are given in [Table 3](#T0003){ref-type="table"}.

###### 

Tyrosinase inhibition activity of *H. rhamnoides* and *C. fistula* extracts

  Plant extracts    Tyrosinase inhibition   
  ----------------- ----------------------- ------------
  *H. rhamnoides*   72.57 ±0.34^a^          45.9
  *C. fistula*      77.64 ±0.62^b^          39.2
  Control           Kojic acid              6.00 ±0.01

All values were based on three different samples. All assays were determined in triplicates per run and data presented as mean ± SD. For column of each sample, values followed by the same letter are not significantly different at p \< 0.05

###### 

Tyrosinase inhibitory effect of formulations (*n* = 3)

  Formulation   Tyrosinase inhibitory effect \[%\]
  ------------- ------------------------------------
  F1            58.6 ±0.425
  F2            64.0 ±0.107
  F3            0

F1 -- Formulation containing H. rhamnoides extract, F2 -- formulation containing C. fistula extract, F3 -- placebo

Patch test {#S20019}
----------

There was no severe response of itching/irritation in any volunteer, mild response for formulation F1 and F2 occurred in 4 volunteers each, moderate erythema occurred in 2 and 4 volunteers, whereas no itching/irritation occurred in 19 and 17 volunteers, respectively, as shown in [Table 4](#T0004){ref-type="table"}.

###### 

Score allocated by volunteers to formulations on the basis of itching/irritation

  Formulation type   Score           
  ------------------ ------- --- --- ---
  F1                 19      4   2   0
  F2                 17      4   4   0

*In-vivo* tyrosinase inhibitory activity of formulations (mexametric evaluation) {#S20020}
--------------------------------------------------------------------------------

The percent changes for the skin melanin following the 12 weeks' treatment with F1 and F3 along with statistical analysis are shown in [Figure 1](#F0001){ref-type="fig"}. The percent changes for the skin melanin following the 12 weeks' treatment with F2 and F3 along with statistical analysis are shown in [Figure 2](#F0002){ref-type="fig"}.

![Percentage of changes produced in skin melanin after the application of F3 (placebo) and F1 (*H. rhamnoides*)](PDIA-30-21266-g001){#F0001}

![Percentage of changes produced in skin melanin after the application of F3 (placebo) and F2 (*C. fistula*)](PDIA-30-21266-g002){#F0002}

In the case of F1 and F3, it was noted that F3 has shown a mean initial change in melanin (2.52%) after the 1^st^ week and the effect remained on the increase after the 12^th^ week up to 5.8% compared to the baseline melanin values of the 25 volunteers.

In contrast to the F3 treatment effects, an excellent reduction in the skin melanin was noticed after treatment with F1, i.e. --3.5% mean initial reduction in melanin after the 1^st^ week of treatment, --7.0% reductions after 1 month, and --16.35% reductions in melanin at the end of the 12^th^ week compared to baseline values. When one-way analysis of variance, ANOVA (Kruskal-Wallis test) was applied, there was a high significant (*p* \< 0.0001) difference between F1 and F3. When Dunn\'s multiple comparison tests were applied, there were insignificant (*p* \> 0.05) differences between various time intervals.

F2 produced a noticeable reduction in melanin with an initial mean reduction of --7.07% after the 1^st^ week and the effect was maintained until the 12^th^ week up to --13.0%, compared to the baseline skin melanin values of the 25 volunteers. When one-way analysis of variance, ANOVA (Kruskal-Wallis test) was applied, there was a significant (*p* \< 0.0001) difference between F2 and F3. When Dunn\'s multiple comparison tests were applied, there were insignificant (*p* \> 0.05) differences between various time intervals except the 2^nd^ and 4^th^ week and the 1^st^ and 12^th^ week, where significant results were obtained.

Visual survey {#S20021}
-------------

Subjectively using a visual survey, the number of volunteers who responded to various parameters is shown in [Table 5](#T0005){ref-type="table"} for F1, F2, F3. In the paired sample *t*-test, an in-significant difference between the three conditions was observed, which showed that there was no variation between the active formulations.

###### 

Visual survey of formulations

  Parameter                Condition   F1 (*n* = 25)   F2 (*n* = 25)   F3 (*n* = 25)   Value of *p*
  ------------------------ ----------- --------------- --------------- --------------- --------------
  Change in photograph     Improved    14              19              0               0.08
  Not improved             10          4               44                              
  Deteriorated             1           2               6                               
  Change in size           Improved    18              20              0               0.057
  Not improved             5           4               40                              
  Deteriorated             2           1               10                              
  Change in pigmentation   Improved    18              19              0               0.055
  Not improved             6           5               36                              
  Deteriorated             1           1               14                              
  Net result               Improved    21              22              0               0.061
  Not improved             3           2               42                              
  Deteriorated             2           1               8                               

Discussion {#S0022}
==========

Hyperpigmentation is one of the most common skin disorders. An increase in melanin synthesis or an irregular distribution of melanin results in hyperpigmentation or spots, especially on the face. Melasma is an example of pigmentation observed mainly in females, though in Asia it is commonly seen in males as well. It is more common in South Asian countries due to skin type IV to V (darker complexion) and increased UV radiation. Treating melasma is challenging and the main treating agent is hydroquinone. The major problem with high concentration (above 4%) of hydroquinone is contact dermatitis. Though various other treatment options are also available, all are very costly with delayed results \[[@CIT0015]\].

Various types of whitening agents are used to treat hyperpigmentation. These agents include arbutin, hydroquinones, azelaic acid and kojic acid. Though these agents are effective, they have side effects. A change has been observed recently to use plant extracts as skin-whitening agents in different types of formulations \[[@CIT0016]\].

![**A** -- Baseline photo of a patient treated with F1. **B** -- Clinical improvement seen after 12 weeks of therapy with F1](PDIA-30-21266-g003){#F0003}

![**A, B** -- Baseline photos of patients treated with F2. **C, D** -- Clinical improvement seen after 12 weeks of therapy with F2](PDIA-30-21266-g004){#F0004}

It has been reported by several researchers that plants rich in alkaloids, flavonoids, unsaturated fatty acids (linoleic acid, oleic acid) and mineral have anti-tyrosinase activity \[[@CIT0017], [@CIT0018]\]. Similarly, catechins, including (+)-gallocatechin, (--))-epicatechin, (--))-epigallocatechin (EGC), (--)) epicatechin gallate (ECG) and (--))-epigallocatechin gallate (EGCG) are studied for anti-tyrosinase activity \[[@CIT0019]\].

Both plants, *H. rhamnoides* and *C. fistula*, are reported to contain catechins, gallic acid, flavonoids, quercetin, organic acids (linoleic acid, oleic acid). The reduction in skin melanin (anti-melasma effects) can be credited to these constituents present in F1 and F2.

Conclusions {#S0023}
===========

The good agreement between the results of *in-vitro/in-vivo* evaluations and those of visual surveys showed that the plant extracts demonstrate efficacy in comparison to placebo in whitening the skin as well as melasma on the face of patients. The plant extracts, which demonstrated a significant tyrosinase inhibitory activity, were described for the first time to possess this biological property. In Pakistan, where sun exposure is severe, the possibility of developing melasma is higher. Instead of expensive and risky treatments, there is a demand for natural remedies which are cheaper and effective. *H. rhamnoides* and *C. fistula*, therefore, offer a possible solution to the problem.
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